DE60310646D1 - Verfahren und Zusammensetzungen zur Stabilisierung des Brain-Natriuretic-Peptids (BNP) in Blutproben - Google Patents

Verfahren und Zusammensetzungen zur Stabilisierung des Brain-Natriuretic-Peptids (BNP) in Blutproben

Info

Publication number
DE60310646D1
DE60310646D1 DE60310646T DE60310646T DE60310646D1 DE 60310646 D1 DE60310646 D1 DE 60310646D1 DE 60310646 T DE60310646 T DE 60310646T DE 60310646 T DE60310646 T DE 60310646T DE 60310646 D1 DE60310646 D1 DE 60310646D1
Authority
DE
Germany
Prior art keywords
bnp
phe
arg
inhibitors
samples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60310646T
Other languages
English (en)
Other versions
DE60310646T2 (de
Inventor
Alexander New York Belensky
Barry Bluestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of DE60310646D1 publication Critical patent/DE60310646D1/de
Application granted granted Critical
Publication of DE60310646T2 publication Critical patent/DE60310646T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Peptides Or Proteins (AREA)
DE60310646T 2002-06-19 2003-06-18 Verfahren und Zusammensetzungen zur Stabilisierung des Brain-Natriuretic-Peptids (BNP) in Blutproben Expired - Lifetime DE60310646T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38999102P 2002-06-19 2002-06-19
US389991P 2002-06-19

Publications (2)

Publication Number Publication Date
DE60310646D1 true DE60310646D1 (de) 2007-02-08
DE60310646T2 DE60310646T2 (de) 2007-10-04

Family

ID=29720441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310646T Expired - Lifetime DE60310646T2 (de) 2002-06-19 2003-06-18 Verfahren und Zusammensetzungen zur Stabilisierung des Brain-Natriuretic-Peptids (BNP) in Blutproben

Country Status (8)

Country Link
US (1) US20040067889A1 (de)
EP (1) EP1378242B1 (de)
JP (1) JP2004029021A (de)
AT (1) ATE349219T1 (de)
AU (1) AU2003204649A1 (de)
CA (1) CA2430889A1 (de)
DE (1) DE60310646T2 (de)
ES (1) ES2279911T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097237A2 (en) * 2002-05-13 2003-11-27 Becton, Dickinson, And Company Protease inhibitor sample collection system
US8071560B2 (en) * 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
AU2003268531A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7291501B2 (en) 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
US7445933B2 (en) 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
EP1727556A2 (de) * 2004-02-17 2006-12-06 University Of South Florida Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen
CN101163970A (zh) * 2004-12-21 2008-04-16 耶鲁大学 先兆子痫的诊断
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides
WO2007003594A1 (en) * 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
WO2007098184A2 (en) * 2006-02-21 2007-08-30 Nanogen, Inc. Methods and compositions for analyte detection
JP5065828B2 (ja) * 2006-09-26 2012-11-07 三菱化学メディエンス株式会社 ディプロチンａを含有する採血管及びそれを用いる測定法
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
FI20075251A0 (fi) * 2007-04-13 2007-04-13 Hytest Oy Immunomääritys epästabiilien antigeenien määrittämiseksi
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN102798691A (zh) * 2011-05-21 2012-11-28 中国科学院大连化学物理研究所 一种检测血中苯丙氨酸二肽的新方法
JP7407659B2 (ja) 2019-05-30 2024-01-04 塩野義製薬株式会社 プロテアーゼ阻害剤を含有するｂｎｐ測定用標準品
CN113671197B (zh) * 2021-08-19 2023-08-08 四川沃文特生物技术有限公司 一种缓冲液、校准品、试剂盒、制备方法及用途
CN116718762A (zh) * 2023-06-09 2023-09-08 上海品峰医疗科技有限公司 一种多肽类样本稳定剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096811A (en) * 1986-03-12 1992-03-17 Genentech, Inc. Novel assay system for measuring human plasminogen actuator activity
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
US5541116A (en) * 1991-09-30 1996-07-30 B.R.A.H.M.S. Diagnostica Gmbh Method for the stabilization of endogenous, physiologically active peptides
JP3555961B2 (ja) * 1991-12-25 2004-08-18 第一サントリーファーマ株式会社 安定なペプチド医薬組成物
AU751660B2 (en) * 1997-10-24 2002-08-22 Shionogi & Co., Ltd. Method for inhibiting decomposition of natriuretic peptides and improved method for assaying natriuretic peptides with the use of the same
US6835814B1 (en) * 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias

Also Published As

Publication number Publication date
CA2430889A1 (en) 2003-12-19
EP1378242A1 (de) 2004-01-07
AU2003204649A1 (en) 2004-01-15
US20040067889A1 (en) 2004-04-08
EP1378242B1 (de) 2006-12-27
JP2004029021A (ja) 2004-01-29
DE60310646T2 (de) 2007-10-04
ES2279911T3 (es) 2007-09-01
ATE349219T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
ATE349219T1 (de) Verfahren und zusammensetzungen zur stabilisierung des brain-natriuretic-peptids (bnp) in blutproben
FR23C1024I1 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
CY1119853T1 (el) Χρηση στρωματικων βλαστοκυτταρων λαμβανομενων απο ιστο αδιποζης στην θεραπεια συριγγιου
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE508745T1 (de) Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund
HK1115438A1 (en) Test element comprising nanofibres
EP1907845A4 (de) Diagnose von krankheiten und leiden durch analyse histopathologisch aufbereiteter biologischer proben unter verwendung flüssiger gewebepräparationen
SI1587821T1 (sl) Sestavki in postopki za stabiliziranje transtiretina in zaviranje napaäśnega zvijanja transtiretina
WO2006090385A3 (en) Protease inhibitors and method of screening thereof
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
IL182644A0 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
ATE471326T1 (de) Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
PT1596192E (pt) Processo de separação de proteínas através de eletroforese capilar e composições tampão para eletroforese capilar
EA200800667A1 (ru) Аптамеры, связывающие тромбин с высокой аффинностью
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
WO2007106893A3 (en) Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
ATE542804T1 (de) 5-phenyl-pentansäurederivate als matrixmetalloproteinase-inhibitoren zur behandlung von asthma und anderen erkrankungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
EA200600561A1 (ru) Фармацевтический препарат для лечения шока
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
EP1860438A4 (de) Verfahren zur identifizierung des zielproteins eines wirkstoffs und verfahren zum screening eines therapeutischen wirkstoffs gegen diabetes mittels des zielproteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SIEMENS HEALTHCARE DIAGNOSTICS INC. (N.D.GES.D, US

8328 Change in the person/name/address of the agent

Representative=s name: MAIER, D., DIPL.-ING. UNIV., PAT.-ASS., 81739 MUEN